Evidence map›Paper›PMID 31350683›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

Expression of Concern: BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.

M Cuadros, V Sánchez-Martín, A Herrera-Merchan, C Baliñas, J Martín-Padrón, L Boyero, P Peinado, P P Medina

Open access · greenAbstract readNewsExpression of Concern
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

M CuadrosDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.
V Sánchez-MartínDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.ORCID http://orcid.org/0000-0003-1501-6681
A Herrera-MerchanGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
C BaliñasGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
J Martín-PadrónDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.
L BoyeroDepartment of Biochemistry and Molecular Biology III and Immunology, University of Granada, Granada, Spain.
P PeinadoGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
P P MedinaGENYO, Centre for Genomics and Oncological Research, Granada, Spain.
Universidad de Granada · ESPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID31350683
OpenAlexW2964620895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.